Lifecore Biomedical, Inc. (Lifecore Injectables CDMO)

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products and medical devices. The company's mission centers on partnering with customers to develop and manufacture life-changing pharmaceuticals. Its corporate headquarters are situated in Chaska, Minnesota, United States.

Lifecore provides comprehensive CDMO services, encompassing specialty formulation, aseptic filling, and final packaging for complex sterile injectable products, available in various formats such as syringes, vials, and cartridges. A core component of its business is the production of pharmaceutical-grade, non-animal-sourced sodium hyaluronate (HA), which serves as both an active pharmaceutical ingredient (API) and an excipient. This HA is utilized across diverse medical applications, particularly within the ophthalmology, orthopedics, and aesthetics market segments. The company is recognized for its expertise in handling highly viscous formulations.

Recent developments include the appointment of Paul Josephs as President and CEO in March 2024, following a strategic review that affirmed the company's commitment to operating as a standalone entity and increasing investments in aseptic production capacity. Ryan D. Lake assumed the role of CFO in September 2024. Lifecore has been actively expanding its manufacturing capabilities, with projections to more than triple its annual aseptic production capacity by fiscal year 2027. The company has secured new commercial manufacturing agreements, including site transfers for existing products and the expansion into new delivery systems, underscoring its growth strategy within the CDMO sector.